Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL728548 | 0.84 | MAPT (0.41) | MAPTALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL25001918 | 0.81 | MAOA (0.47) | MAPTIDO1EPHB3KMT2AMEN1 | |
| SCHEMBL31177965 | 0.81 | MAOA (0.47) | MAPTIDO1EPHB3KMT2AMEN1 | |
| SCHEMBL6966695 | 0.80 | MAPT (0.42) | MAPTIDO1EPHB3KMT2AMEN1 | |
| SCHEMBL28648630 | 0.78 | ALDH1A1 (0.39) | MAPTIDO1KMT2AMEN1MAPK1 | |
| SCHEMBL11187663 | 0.77 | CYP1A2 (0.39) | MAPTKMT2ASMN1; SMN2LMNA | |
| SCHEMBL1826516 | 0.77 | MAPT (0.61) | MAPTKMT2AMEN1ALDH1A1ADRA2B | |
| SCHEMBL9412138 | 0.76 | LMNA (0.44) | MAPTKMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1116563 | 0.76 | IDO1 (0.48) | MAPTIDO1KMT2AMEN1ALDH1A1 | |
| SCHEMBL9396474 | 0.75 | MAPT (0.42) | MAPTKMT2AMEN1MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168969-A2 | Racemization and Enantiomer Separation of Clopidogrel | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-03-31 | — | — | EP | disclosed |
| EP-1483269-B1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | TEVA PHARMA (IL) | 2009-10-14 | — | — | EP | disclosed |
| US-7259261-B2 | Racemization and enantiomer separation of clopidogrel | TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság (HU) | 2007-08-21 | — | — | US | disclosed |
| US-20050049275-A1 | Racemization and enantiomer separation of clopidogrel | ENTIRE INTEREST | 2005-03-03 | — | — | US | disclosed |
| EP-1483269-A1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | Teva Pharmaceutical Industries Limited (IL) | 2004-12-08 | — | — | EP | disclosed |
| US-6800759-B2 | REACTING MIXTURE OF (R) AND (S) CLOPIDOGREL FREE BASE WITH LEVOROTATORY CAMPHORSULFONIC ACID IN C5 TO C12 HYDROCARBON TO PRECIPITATE (S) CLOPIDOGREL CAMPHORSULFONATE, CONVERTING TO FREE BASE, PRECIPITATING CLOPIDOGREL BISULFATE IN SOLVENT | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-10-05 | — | — | US | disclosed |
| US-6737411-B2 | CRYSTALLIZING AS CAMPHOR SULFONATE SALT; CONVERTING PURIFIED MATERIAL BACK TO FREE BASE FORM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-05-18 | — | — | US | disclosed |
| WO-2004013147-A1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-02-12 | — | — | WO | disclosed |
| US-20040024012-A1 | Racemization and enantiomer separation of clopidogrel | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-02-05 | — | — | US | disclosed |
| US-20040024011-A1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | TEVA PHARMACEUTICALS USA, INC. | 2004-02-05 | — | — | US | disclosed |
| US-4420619-A | Imidazole urea and amido compounds | CIBA-GEIGY CORPORATION (US) | 1983-12-13 | — | — | US | disclosed |
| US-4343810-A | Method of inhibiting sickling of sickle erythrocytes using 2-((haloanilino)methyl)-2-imidazolines | THE DOW CHEMICAL COMPANY (US) | 1982-08-10 | — | — | US | disclosed |
| EP-0004561-B1 | UREA AND AMIDE DERIVATIVES, THEIR PREPARATION, PHARMACEUTICALS CONTAINING THEM AND THEIR USE FOR PREPARING PHARMACEUTICAL COMPOSITIONS | CIBA-GEIGY AG (CH) | 1981-11-04 | — | — | EP | disclosed |
| US-4292429-A | Imidazole urea and amido compounds | CIBA-GEIGY CORPORATION (US) | 1981-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024012-A1 | Racemization and enantiomer separation of clopidogrel | SRR, TBXA2R, PTGIR | MAPT 4200/4885IDO1 2530/4885EPHB3 1028/4885 |
| US-20040024011-A1 | RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL | SRR, TBXA2R, PTGIR | MAPT 4200/4885IDO1 2530/4885EPHB3 1028/4885 |
| US-20050049275-A1 | Racemization and enantiomer separation of clopidogrel | SRR, TBXA2R, PTGIR | MAPT 4200/4885IDO1 2530/4885EPHB3 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.